Lipidomics paves the way to groundbreaking scientific discoveries

VIB’s Technology Watch team has been active for almost a decade, continuously analyzing the potential of emerging technologies and mediating researchers’ access to them. By expanding VIB’s network of technology suppliers, purchasing licenses and negotiating business partnerships, the Tech Watch team enables VIB scientists to have privileged access to cutting-edge scientific innovations. One example comes in the form of a powerful lipidomics research tool made available to VIB scientists through a collaboration with Lipotype, a Max-Planck spin-off and key service provider. Since 2015, Lipotype technology has been a crucial factor in several major breakthroughs in multiple life sciences domains.

The benefits of a dedicated lipidomics collaborator
Lipidomics, or the analysis, identification and quantification of lipids, has important applications in basic and clinical research, as well as in the nutrition, cosmetics and personalized healthcare industries. Using Lipotype’s Shotgun Lipidomics Technology, researchers can rapidly analyze large samples at reasonable prices, benefiting from the ultra-broad coverage and absolute quantification of lipids enabled by this technology.

Mark Veugelers (VIB Tech Watch): “The Tech Watch team, in close collaboration with VIB group leaders, is constantly on the lookout for new technologies that can have a major impact on our research. The Lipidomics services Lipotype offers is a good example. But identification of a novel technology with potential isn’t enough to produce breakthrough results. Key in the process is the hands-on experience of VIB scientists when evaluating the potential of these novel technology opportunities.

Oliver Uecke (Lipotype): “Tech Watch at VIB is a fantastic instrument to support technology transfer.  It’s a win-win situation for all parties involved: VIB researchers get access to innovative technologies early on, while technology providers have the tech watch team as single entry point to address the VIB collective of researchers. VIB profits from providing their researchers with means to generate cutting edge research results and with an improved basis for licensing and spin-off creation.”

Better tech integration, impactful results
After just two years of collaboration, VIB scientists working with Lipotype have published three papers in high-impact academic journals. This demonstrates the fact that partnerships between VIB and specialized tech service providers and the integration of new innovations into VIB research leads to more and faster discoveries.

Prof. Wim Annaert (VIB-KU Leuven): “Lipotype’s Shotgun technology was critical to our recent paper on a new approach to analyzing subcellular dysfunction. Our next challenge is now to integrate lipidomics with proteomics data to better understand what goes on at the level of a single subcellular compartment for instance in a disease context.”
(relevant publication: A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: the case of NPC1 deficiency, Tharkeshwar et al., Scientific Reports 2017)

Prof. Patrik Verstreken (VIB-KU Leuven): “My team recently made groundbreaking discoveries related to mitochondrial defects in Parkinson’s Disease. Tech Watch – and access to Lipotype tech in particular – were essential to these findings.”
(relevant publication: Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency, Vos et al., J Cell Biol 2017)

Prof. Rose Goodchild (VIB-KU Leuven): “Tech Watch funding significantly boosted our confidence in collaborating with Lipotype for our work on cellular lipid metabolism. Lipidomics is a key emerging technology that we don’t have in-house, and our access to it – especially when it comes to molecular and cellular research – adds huge value to our projects.”
(relevant publication: Torsins Are Essential Regulators of Cellular Lipid Metabolism, Gonzalez et al., Developmental Cell 2016)

Read the full press release here
 Open Adobe PDF Version
 Download the Microsoft Word Version


About Lipotype

Lipotype is a spin-off company from the Kai Simons and Andrej Shevchenko labs of the world-renowned Max-Planck-Institute of Molecular Cell Biology and Genetics in Dresden, Germany. Drawing on many years of cutting edge research experience, Lipotype delivers comprehensive, absolutely quantitative lipid analysis services for clinical and biological samples on a high-throughput scale.

Lipotype offers high quality lipid analysis services for a wide range of customers and applications including biomarker identification for clinical researchers, pharma and biotech companies, functional food development for the food industry, as well as for the small-scale profiling needs of academic researchers.

Follow us on  LinkedIn Twitter or  subscribe to our newsletter

Largest skin lipidomics study provides a basis for personalized cosmetics

The largest lipidomics study to date analyzing skin lipids in more than 250 skin samples has been published in “Scientific Reports” (Sadowski T. et al. “Large-scale human skin lipidomics by quantitative, high-throughput shotgun mass spectrometry.” Scientific Reports 2017, doi: 10.1038/srep43761). The study applied a novel Skin Lipidomics Technology Platform developed by Lipotype GmbH, a German Max-Planck-Institute spin-off. Results showed that the skin lipidome varies with respect to sampling depth, site, age and subject. This variation seems to be driven, mainly by secretion of sebaceous lipids and this finding could have an intriguing impact on the design of cosmetic products. Results also reveal a high inter-individual variation of the lipid profile of each person, which could become the basis for the development of personalized cosmetics.  Read more

Discover how skin lipidomics can be applied for your research and product development and get the White Paper.

Meet us at in-cosmetics in London (04th -06th of April 2017): Schedule an individual appointment

Meet the Lipotype team in 2017!

02.-06. December 2017
 ASCB 2017, Philadelphia, USA 
We will attend ASCB 2017! Come and visit us at our booth 1000!

Or attend the Tech Talk of Dr. Michal Surma on the 4th of December at 8:15 am about Lipotype Shotgun Lipidomics technology for comprehensive, high-throughput lipid analysis located in Theater 2.


12.-14. November 2017
 3. Lipidomics Forum, Borstel, Germany 
Dr. Michal Surma, Head of Analytical Services, will inform about skin lipidomics during a talk. 


06.-08. November 2017
Bio-Europe, Berlin, Germany 
We will attend the 23rd Annual International Partnering Conference. 


23.-25. October 2017
24th Conference of the International Federation of Societies of Cosmetic Chemists, Seoul, South Korea
Lipotype will be present at the IFSCC 2017 and we will give a presentation about A high-throughput Shotgun Lipidomics Technology for the quantitative analysis of tape-stripped human stratum corneum lipid profiles


04.-08. June 2017
Dr. Christian Klose will attend the conference and will hold a poster presentation about Lipid parameters associated with obesity identified using a high-throughput Shotgun Lipidomics technology at Tuesday, the 6th of June. 


16.-18. May 2017
Biotechnica 2017, Hannover, Germany
Meet the Lipotype team at their booth (Hall 20, Stand A12/9) at Biotechnica 2017 in the Innovation Zone where we inform you about our Shotgun Lipidomics Technology. 


05.-06. April 2017
Deutsche Biotechno- logietage, Hannover, Germany
Dr. Christian Klose, Head of R&D, will participate and talk about Innovative Lipid Analysis for Cosmetics and Dermatology Applications on the second day of the conference.


04.-06. April 2017
in-cosmetics global, London, UK
Dr. Oliver Uecke and Tomasz Sadowski will participate to find new cooperation partners and customers to inform about our novel skin Lipidomics for cosmetic and dermatological applications


30.-31. March 2017
Workshop on the Role of Lipids in Autophagy, Copenhagen, Denmark
This workshop will take place at the Danish Cancer Society Research Center in Copenhagen. Prof. Kai Simons, Founder and CEO of Lipotype, will hold a presentation about ‘Lipidrafts to clinical Lipidomics’. We hope he will have some fruitful discussions.


If you want to schedule an individual meeting drop us a line



Lipotype is sponsoring the following Events:

26. February -02. March 2017
Keystone Symposia, California, USA
Lipidomics and Bioactive Lipids in Metabolism and Disease (B6)


10.-12. May 2017
36th Summer Symposium in Molecular Biology, Pennsylvania, USA
Metabolism: Disease Models and Model Organisms


Two publications of researchers at the Flanders Institute of Biotechnology (VIB) with Lipotype lipidomics

Lipotype Shotgun Lipidomics coupled with the novel superparamagnetic nanoparticles-based organelle purification uncovers lipid composition of plasma membrane and endosomes in storage disorder diseases.

A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: the case of NPC1 deficiency – Scientific Reports, 2017
Arun K. Tharkeshwar, Jesse Trekker, Wendy Vermeire, Jarne Pauwels, Ragna Sannerud, David A. Priestman, Danielle te Vruchte, Katlijn Vints, Pieter Baatsen, Jean-Paul Decuypere, Huiqi Lu, Shaun Martin, Peter Vangheluwe, Johannes V. Swinnen, Liesbet Lagae, Francis Impens, Frances M. Platt, Kris Gevaert, Wim Annaert 

Lipotype Shotgun Lipidomics applied to mitochondria helps to link the lipid metabolism with the electron transport via action of phosphatase and tensin homologue–induced kinase (PINK1), a protein associated with Parkinson’s disease.

Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency – The Journal of Cell Biology, 2017
Melissa Vos, Ann Geens, Claudia Böhm, Liesbeth Deaulmerie, Jef Swerts, Matteo RossiKatleen Craessaerts, Elvira P. Leites, Philip Seibler, Aleksandar Rakovic, Thora Lohnau, Bart De Strooper, Sarah-Maria Fendt, Vanessa A. Morais, Christine Klein, Patrik Verstreken

Read more about research at VIB:


Launch of BEAt-DKD

An Innovative Medicines Initiative (IMI) Project for Precision Medicine in Diabetic Kidney Disease

with Lipotype as project partner


BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership funded by the Innovative Medicines Initiative (IMI), member companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Juvenile Diabetes Research Foundation (JDRF) and the state of Switzerland has announced the launch of a 5-­­year project (total budget 28.9 Million Euro) with the aim to improve prevention and management of Diabetes Kidney Disease (DKD).

Leading experts from 21 academic institutions, 6 EFPIA pharmaceutical companies, 1 biotech company and JDRF launched BEAt-DKD to provide a holistic systems medicine view of the pathogenesis and heterogeneity of DKD, with the goal to identify targetable mechanisms and pathways underlying initiation and progression of DKD, as well as to identify and validate biomarkers of disease progression and treatment responses, representing first steps towards precision medicine in DKD. Lipotype is project partner in this consortium.

Please download the official press release of the BEAt-DKD consortium here

Lipotype measures lipidomes for protein-lipid interaction study

Zhou et al. show that K-Ras C-terminal membrane anchor encodes an previously unsuspected anionic lipid binding specificity, which is realized by defined conformational structures of the anchor. Subtle changes to anchor sequence or prenylation profoundly alter its lipid specificity and is a key determinant of K-Ras signal output.

Lipotype is proud of its contribution to this exciting study.

Read the whole publication here:

Lipid-Sorting Specificity Encoded in K-Ras Membrane Anchor Regulates Signal Output – Cell, 2017
Yong Zhou, Priyanka Prakash, Hong Liang, Kwang-Jin Cho, Alemayehu A. Gorfe, John F. Hancock

Lipotype and Lund University publish about lipid profiles in Diabetes and infarction

In the latest issue of the Journal of the American Heart Association, Lipotype and Lund University published a paper in which high-throughput lipidomic screening was successfully applied to reveal molecular lipid profiles in blood serum specific for Diabetes mellitus and myocardial infarction.

Read the whole publication here:

Identification of Shared and Unique Serum Lipid Profiles in Diabetes Mellitus and Myocardial Infarction, , 2016
Sanela Kjellqvist, Christian Klose, Michal A. Surma, George Hindy, Inês G. Mollet, Anna Johansson, Patrick Chavaux, Johan Gottfries, Kai Simons, Olle Melander and Céline Fernandez